Carl Johnson, MD
Ophthalmology · Parker, CONPI 1851320485
Payments from drug & device makers
What this record shows
This record is dominated by other: $4,677 of the $6,981 with a category attached, or 67.0%. Carl Zeiss Meditec USA, Inc. accounts for 69.0% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2021 at $5,010 and has fallen 93.9% since, to $308 in 2025.
Across 61 payments — averaging $114.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec USA, Inc.$5K
- Alcon$729
- Rxsight Inc$443
- Bausch & Lomb, A Division Of Bausch Health US, LLC$185
- Omeros Corporation$129
- Sight Sciences, Inc.$128
- plus $550 from 10 others
Across 7 payments — averaging $318.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$2K
What the payments were for
- Speaking & faculty fees$511%
- Food & beverage$2,25032%
- Gifts$30%
- Other$4,67767%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec USA, Inc. | 2 | $4,817 |
| Alcon | 13 | $729 |
| Rxsight Inc | 5 | $443 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $185 |
| Omeros Corporation | 6 | $129 |
| Sight Sciences, Inc. | 1 | $128 |
| Novartis | 7 | $123 |
| AbbVie(2 entities) | 6 | $111 |
| Rayner Intraocular Lenses Limited | 1 | $93 |
| Sun Pharmaceutical Industries Inc. | 3 | $57 |
| Kala Pharmaceuticals, Inc. | 2 | $42 |
| Ocular Therapeutix, Inc. | 2 | $36 |
| Eyevance Pharmaceuticals LLC | 2 | $29 |
| Amgen | 2 | $25 |
| Iridex Corporation | 1 | $19 |
| Thea Pharma Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IOLMaster 700$4,677
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$246
- Unity$146
- RXSIGHT CONTACT LENS$143
- RXSIGHT INJECTOR CARTRIDGE$143
- RXSIGHT INJECTOR HANDPIECE$143
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$143
- LIGHT ADJUSTABLE LENS (LAL)$143
- FORUM$140
- AcrySof IQ PanOptix$131
- OMNI(R) SURGICAL SYSTEM (US)$128
- ReSTOR$120
- Wavelight Refractive Suite$111
How this compares
$6,981 in reported general payments places this provider in the 85th percentile of 262 ophthalmology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 38 | $58,381 |
| Lotemax SmLoteprednol Etabonate | 145 | $37,163 |
| Prednisolone Acetate | 234 | $14,009 |
| LotemaxLoteprednol Etabonate | 14 | $10,026 |
| Loteprednol Etabonate | 36 | $8,594 |
| ZirganGanciclovir | 15 | $8,275 |
| Fluorometholone | 80 | $7,567 |
| TobradexTobramycin/Dexamethasone | 26 | $7,317 |
| LumiganBimatoprost | 13 | $6,349 |
| CombiganBrimonidine Tartrate/Timolol | 13 | $4,284 |
| Alphagan PBrimonidine Tartrate | 15 | $4,004 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 15 | $3,214 |
| FlarexFluorometholone Acetate | 17 | $2,206 |
| Travoprost | 14 | $2,101 |
| Ofloxacin | 71 | $1,144 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $111 | $73,01779 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Lotemax, Loteprednol Etabonate | $185 | $55,783195 claims |
| Eyevance Pharmaceuticals LLCFlarex | $29 | $2,20617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 262 ophthalmology providers in Colorado.
Other ophthalmology in Parker
- Carl TubbsParker$6K
- Mark PackerBoulder$3.5M
- Jon DishlerGreenwood Village$1M
- Mark DaceyDenver$370K
- Cristos IfantidesDenver$343K
- Geeta Lalchandani LalwaniBoulder$319K
- Richard DavidsonAurora$316K
- Steven DeweyColorado Springs$246K
- Jack ZamoraDenver$172K
- Eva KimDenver$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.